CN115484958A - 用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合 - Google Patents

用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合 Download PDF

Info

Publication number
CN115484958A
CN115484958A CN202180030907.0A CN202180030907A CN115484958A CN 115484958 A CN115484958 A CN 115484958A CN 202180030907 A CN202180030907 A CN 202180030907A CN 115484958 A CN115484958 A CN 115484958A
Authority
CN
China
Prior art keywords
weeks
lsd
nivolumab
response
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180030907.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·菲尔瓦夫
I·阿龙奇克
T·周
E·奥尔森
B·福克斯
M·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Quanticel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanticel Pharmaceuticals Inc filed Critical Quanticel Pharmaceuticals Inc
Publication of CN115484958A publication Critical patent/CN115484958A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180030907.0A 2020-03-06 2021-03-05 用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合 Pending CN115484958A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986541P 2020-03-06 2020-03-06
US62/986,541 2020-03-06
PCT/US2021/021101 WO2021178807A1 (en) 2020-03-06 2021-03-05 Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc

Publications (1)

Publication Number Publication Date
CN115484958A true CN115484958A (zh) 2022-12-16

Family

ID=77614361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030907.0A Pending CN115484958A (zh) 2020-03-06 2021-03-05 用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合

Country Status (11)

Country Link
US (1) US20230089536A1 (enExample)
EP (1) EP4114398A1 (enExample)
JP (1) JP2023516745A (enExample)
KR (1) KR20220151637A (enExample)
CN (1) CN115484958A (enExample)
AU (1) AU2021230575A1 (enExample)
BR (1) BR112022017637A2 (enExample)
CA (1) CA3170456A1 (enExample)
IL (1) IL296564A (enExample)
MX (1) MX2022010912A (enExample)
WO (1) WO2021178807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
WO2021095835A1 (en) 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
US20250049757A1 (en) * 2021-09-30 2025-02-13 Taiho Pharmaceutical Co. Ltd. Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315187A1 (en) * 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
WO2019104381A1 (en) * 2017-11-29 2019-06-06 University Of Canberra Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd1 binding antagonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
MX2021015447A (es) * 2019-06-13 2022-04-06 Celgene Corp Métodos de tratamiento del cáncer dirigidos a tumores fríos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150315187A1 (en) * 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
WO2019104381A1 (en) * 2017-11-29 2019-06-06 University Of Canberra Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd1 binding antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FREDERIK KREFTING等: "Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer", 《ONCOLOGY RESEARCH AND TREATMENT》, vol. 42, no. 5, pages 243 - 255, XP055805984, DOI: 10.1159/000499321 *
YUAN FANG等: "LSD1/KDM1A inhibitors in clinical trials: advances and prospects", 《JOURNAL OF HEMATOLOGY ＆ ONCOLOGY》, vol. 12, no. 1, pages 1 - 14 *

Also Published As

Publication number Publication date
EP4114398A1 (en) 2023-01-11
WO2021178807A1 (en) 2021-09-10
BR112022017637A2 (pt) 2022-11-08
AU2021230575A1 (en) 2022-10-20
KR20220151637A (ko) 2022-11-15
CA3170456A1 (en) 2021-09-10
IL296564A (en) 2022-11-01
US20230089536A1 (en) 2023-03-23
MX2022010912A (es) 2022-11-09
JP2023516745A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
JP7653398B2 (ja) 癌を処置するためのグルタミン酸調節剤と免疫療法の併用
BR122022015975B1 (pt) Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
CN115484958A (zh) 用于治疗sclc或sqnsclc的lsd-1抑制剂和纳武单抗的组合
TW202408573A (zh) 使用抗ｐｄ－１抗體與抗ｃｔｌａ－４抗體之組合以治療肺癌
US20200277387A1 (en) Methods and compositions for treating cancer
CN110366562A (zh) 使用抗pd-l1抗体和抗雄激素治疗癌症的方法
JP2019517504A (ja) 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断
JP7749667B2 (ja) 肺がんを治療するためのｋｒａｓｇ１２ｃ阻害剤及びｐｄ－ｌ１結合アンタゴニストを含む方法及び組成物
JP2024016209A (ja) 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ
CN115151258A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
US20230070988A1 (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
CN113677402A (zh) 治疗肿瘤的方法
TW202541838A (zh) 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途
CN112915202B (zh) 喹啉衍生物与pd-1单抗的药物组合
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
JP2024144605A (ja) がんを処置するための方法および組成物
Hays The Development, Efficacy and Safety Profiles of Bispecific Antibodies for Solid Tumors: Amivantamab for EGFR-mutant NSCLC and Tebentafusp for Uveal Melanoma
HK40064787A (en) Methods and compositions for treating cancer
BR122024000362A2 (pt) Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221216